Introduction: Colorectal cancer (CRC) can present with luminal obstruction. Preoperative colonic stenting as a bridge to surgery is often considered and may allow for

AIMTo investigated the real-world effectiveness and safety of various regimens of interferon-free treatments in patients infected with hepatitis C virus (HCV).METHODSWe performed an observational study to analyze different antiviral treatments administered to 462 HCV-infected patients, of which 56.7% had liver cirrhosis. HCV RNA after 4 wk of treatment and at 12 wk after treatment sustained virologic response (SVR) as well as serious adverse events (SAEs) was analyzed first for the whole cohort and then separately in patients who met or did not meet the inclusion criteria of a clinical trial (CT-met and CT-unmet, respectively).RESULTSThe most frequently prescribed treatment was simeprevir/sofosbuvir (36.4%), followed by sofosbuvir/ledipasvir (24.9%) and ombitasvir/paritaprevir/ritonavir (r)/dasabuvir (19.9%). Ribavirin (RBV) was administered in 198 patients (42.9%). SVRs occurred in 437/462 patients (94.6%). The SVRs ranged between 93.3% and 100% for genotypes 1-4. SVRs were achieved in 96.2% patients in the CT-met group vs 91.9% patients in the CT-unmet group (P = 0.049). Undetectable HCV RNA at week 4 occurred in 72.9% of the patients. In the univariate analysis, the factors associated with SVRs were lower liver stiffness, absence of cirrhosis, higher platelet count, higher albumin levels, no RBV dose reduction, undetectable HCV RNA at week 4 and CT-met group. In the multivariate analysis, only albumin was an independent predictor of treatment failure (P = 0.04). Eleven patients (2.4%) developed SAEs; 5.2% and 0.7% of the patients in the CT-unmet and CT-met groups, respectively (P = 0.003).CONCLUSIONA high proportion of patients with HCV infection achieved SVRs. For patients who did not meet the CT criteria, treatment regimens must be optimized.

No abstract

An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8–3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0–48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies.

Sphincterotomy 130 Stent 104 ADVERSE EVENTS 83 (22%) Bleeding 27 (6 IR, 19 endoscopy, 2 observed) Infection 15 (13 endoscopic therapy, 1 surgery, 1 antibiotherapy) Perforation 8 (4 endoscopic therapy, 4 surgery) Fistula 3 (2 surgery, 1 endoscopic therapy) Stent Disfunction (migration, dislodgement, misdeployment, occlusion) 9 (1 surgery, 8 endoscopic therapy) Other (anaphylaxis, ischemic colitis, bile duct injury requiring ERCP, ARDS) 4 (1 anaphylaxis, 1 ischemic colitis, 1 bile duct injury, 1 ARDS) CLINICAL SUCCESS 336/370 (91%) DEN PERFORMED 217 (80%) # sessions (mean) 2.45 (range 1-11) ENDOSCOPIC REINTERVENTION REQUIRED 45 (12%) ADDITIONAL NON-ENDOSCOPIC THERAPY REQUIRED 53 (14%) HOSPITAL LOS (days) 16.5 (range 0-123) RESOLUTION OF PFC 340 (92%) Lost to follow-up 10 Ongoing 2 FOLLOW-UP TIME (weeks) 49 (range 0-273)